A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2016
At a glance
- Drugs Icotinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICTAN
- 13 Apr 2016 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023 as reported by ClinicalTrials.gov record.
- 13 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
- 01 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.